

PHYSICO-CHEMICAL CHARACTERIZATION AND IN VIVO PHARMACODYNAMIC EVALUATION OF LYOPHILIZED MELOXICAM: β -CYCLODEXTRIN INCLUSION COMPLEXES

FARZANA S. BANDARKAR^{1*} AND PRADEEP R. VAVIA²

¹Department of Pharmaceutics, Faculty of Pharmacy, Kuwait University, Kuwait, ² Faculty of Pharmacy, University Institute of Chemical Technology, Mumbai, India. Email: farzana_dawre@yahoo.com

Received: 03 Jan 2013, Revised and Accepted: 27 Mar 2013

ABSTRACT

Objective: The objective of the present work was to enhance solubility, in vitro dissolution and in vivo pharmacodynamic activity of meloxicam (MLX) by preparation of lyophilized inclusion complexes with β -cyclodextrin.

Methods: Phase solubility studies were conducted to analyze the influence of β CD on solubility of MLX. Inclusion complexes (ICs) of MLX & β CD were prepared in 2:1, 1:1 and 1:2M ratio followed by in vitro dissolution studies. The amorphous nature of the optimized IC and interaction of MLX with β CD was studied by differential scanning calorimetry (DSC), X-ray diffractometry (XRD) and Fourier transform Infra-Red Spectroscopy (FTIR). The in vivo anti-inflammatory ability of optimized IC was evaluated by carrageenan induced rat paw edema method while the analgesic study was conducted using acetic acid induced writhing test in mice.

Results: Solubility of pure MLX in water at 25°C was found to be only 9.4 μ g/mL. The A_L type of phase solubility curve of MLX with β -CD confirmed the solubility enhancement capability of β CD. Based on the in vitro dissolution studies, 1:1M IC was found to be optimum for further studies. The in vivo anti-inflammatory ability of optimized IC was significantly higher and faster (edema inhibition of 63.36 \pm 6.43% at the end of two hours) as compared to plain MLX (39.75 \pm 4.73% at the end of four hours). Analgesic studies revealed rapid onset of action from optimized IC (73.9% inhibition of writhes in 20 minutes) as compared to that of plain MLX (38.14% inhibition of writhes in 40 minutes).

Conclusion: These results prove that inclusion of MLX in β CD enhances not only the in vitro dissolution of the drug, but also improves its in vivo pharmacodynamic activity.

Keywords: Meloxicam, β -cyclodextrin, Lyophilisation, Dissolution, Analgesic and Anti-inflammatory activity.

INTRODUCTION

Non-steroidal anti-inflammatory drugs (NSAIDs) are still one of the most widely prescribed medications worldwide. As a therapeutic class, they exhibit analgesic, anti-inflammatory, antipyretic and platelet inhibitory properties [1]. However, a vast majority of these drugs have serious side effects such as gastrointestinal (GI) toxicity, gastric mucosal ulcerations and hemorrhage due to inhibition of prostaglandin production [2,3]. The mechanism of action of NSAIDs has been attributed to their ability to inhibit the cyclooxygenase enzyme (Cox). Out of the 2 isoforms of cyclooxygenase, cox-1 is responsible for mediating the production of prostaglandin while cox-2 is primarily associated with inflammation, pain and fever [4]. The traditional NSAIDs are nonselective Cox inhibitors and therefore Cox-2 selective NSAIDs like meloxicam (MLX) are ideal anti-inflammatory agents with minimum drug-related side effects, since they spare the cox-1 activity [5,6]. However, very poor aqueous solubility and wettability of MLX limits the in vivo absorption of the drug leading to variable oral bioavailability [7,8].

Complexation of such hydrophobic pharmaceutical compounds with hydrophilic carriers like cyclodextrin (CDs) leads to altered physicochemical properties of the guest molecule [9-11]. Inclusion complexes (ICs) of drugs with CDs, therefore, have been extensively studied and utilized to improve the solubility, dissolution rate, bioavailability and other desirable properties of poorly water-soluble drugs [12-15]. In the present study, β -cyclodextrin (β CD) was chosen to enhance the solubility of MLX because of its central cavity diameter (6-6.5 Å) which is appropriate to accommodate most aromatic rings, its efficiency in producing stable drug complexes, low toxicity and relatively low cost. Absorption of β CD in an intact form is limited because of its bulky nature and hence, it acts as a true carrier by keeping the hydrophobic drugs in solution and delivering them to the surface of the biological membrane, such as gastrointestinal mucosa, where they partition into the membrane [16-19]. The most commonly used methods for preparation of drug-CD complexes are co-precipitation, solvent evaporation, kneading, physical mixing, spray-drying and lyophilisation [20-24].

The purpose of the present study was to increase the in vitro solubility and dissolution rate, as well as in vivo analgesic and anti-inflammatory activity of MLX, as these activities were never analyzed and reported before [25-28]. To achieve this objective, amorphous ICs of MLX with β CD were prepared in different ratios using the lyophilisation technique, followed by evaluation of *in vitro* dissolution rate [29-32]. Possible physical interaction between the two components were investigated by performing Fourier transform infrared (FTIR) spectroscopy, Differential scanning calorimetry (DSC) and X-ray powder diffraction (XRD) [33,34]. Optimized IC with maximum in vitro release was subjected to in vivo pharmacodynamic studies in animal models.

MATERIALS AND METHODS

Materials

MLX was received as a gift sample by Unichem Lab. Ltd., Mumbai, India. β CD was generously donated by Cerestar, USA. Ultrapure water (Millipore) and analytical grade reagents/ chemicals were used throughout the study.

Phase Solubility Studies

Phase solubility studies were carried out according to the method reported by Higuchi and Connors in order to understand the influence of β CD on solubility of MLX [35,36]. Excess amount of MLX (125 mg) was added in screw-capped conical flasks containing 50 mL of aqueous solution each of different concentrations (0, 0.125, 0.250, 0.375, 0.50, 0.625, 0.75 and 0.875g) of β CD in ultra-pure water. The suspensions were continuously stirred on mechanical shaker (Siena equipment, India) at ambient temperature and 200 rpm for 48 hours (this duration was previously tested to be sufficient to reach equilibrium). The suspensions were filtered through 0.45 μ Millipore membrane filter (Agilent, USA). The filtrates were suitably diluted with water and analyzed, spectrophotometrically (Cecil 2000, UV/Vis spectrophotometer, England), for the dissolved drug at 362 nm. Blank samples of β CD at different concentrations used in the study were analyzed to rule out

interference. All assays were performed in triplicate. The standard curve of MLX in water over a concentration range of 2 to 16 µg/mL at 362 nm was plotted. The mean calibration curve (regression equation: $y = 0.0531x + 0.003$) was found to be linear ($n=6$) with a correlation coefficient of $r^2 = 0.9997$.

The data was treated statistically using linear least square regression and the apparent 1:1 ratio stability constant (K) and the Gibbs free energy (ΔF°) were calculated from the phase-solubility diagram using equations (1) and (2) respectively.

$$K = \frac{\text{slope}}{y \text{ intercept } (1 - \text{slope})} \dots\dots\dots(1)$$

Where, the y- intercept corresponds to the intrinsic solubility of MLX in the absence of β -CD at $25 \pm 1^\circ\text{C}$.

$$\Delta F^\circ = - RT \ln K \dots\dots\dots(2)$$

Where, R is the ideal gas constant and K is the absolute temperature.

Preparation of ICs

The lyophilisation (freeze drying) technique (LABCONCO, Freeze Dry System, Freezone 4.5) was used to prepare ICs of MLX and β CD in 2:1, 1:1 and 1:2 molar ratios. Physical mixture (PM) of MLX and β CD was also prepared in 1:1M ratio by mixing in geometric proportions. The prepared samples were sieved through 60# and stored in air tight containers till further analysis.

Drug content

Content analysis of the samples was performed using UV spectrophotometry. The mean calibration curve of MLX (regression equation: $y = 0.0536x - 0.0036$) in 0.1N sodium hydroxide (NaOH) over a concentration range of 2 to 16 µg/mL at 365 nm was found to be linear ($n=6$) with a correlation coefficient of $r^2 = 0.9999$ and hence it could be employed for routine assay. ICs and PM, containing an equivalent of 15 mg of MLX were dispersed in a suitable quantity of 0.1N NaOH and sonicated (Elma Transonic, 460/H, Germany) for 15 minutes. The filtered samples were suitably diluted with 0.1N NaOH and measured for drug content.

In-vitro dissolution studies

Pure MLX, PM and ICs (equivalent to 15 mg of MLX) were all subjected to dissolution studies ($n = 6$). Dissolution medium was 900ml distilled water (containing 0.02% tween 80 as wetting agent). The test was performed in a USP XXV Type II dissolution apparatus (Erweka DT 80, GmbH, Germany). The stirring speed employed was 100 rpm and the temperature was maintained at $37^\circ\text{C} \pm 0.5^\circ\text{C}$. 5ml aliquots were withdrawn at different time intervals, filtered and measured at 360nm spectrophotometrically, after suitable dilution with the dissolution medium if needed, to determine the amount of drug released. The mean calibration curve of MLX (regression equation: $y = 0.0536x - 0.0036$) in the dissolution medium was found to be linear ($n=6$) over a concentration range of 2 to 16 µg/mL with a correlation coefficient of $r^2 = 0.9995$.

DSC studies

The thermal behavior of MLX, β CD, PM and optimized IC was studied using Perkin Elmer DSC 7 model in aluminum pans under a nitrogen flow of 40 mL/min and heating rate of $10^\circ\text{C}/\text{min}$ in a 20 to 250°C temperature range.

XRD studies

The XRD patterns of MLX, β CD, PM and optimized IC were recorded using Philips X-ray generator (PW 1729) and automatic X-ray diffractometer model PW 1710 unit. The radiation used was Nickel filtered $\text{Cu K}\alpha_1$ radiation having a wavelength of 1.542\AA , operating at 35 K watts and 20 m-amperes in the range (2θ) of 5° to 60° at a scanning rate of $1.2^\circ/\text{min}$.

FTIR studies

FTIR spectroscopic studies of MLX, β CD, PM and optimized IC were conducted by KBr disc method using JASCO FT/IR-5300

Spectrophotometer. The samples were scanned from 4000 to 400 cm^{-1} at room temperature.

In vivo Pharmacodynamic studies [37 - 39]

Anti-inflammatory activity

The anti-inflammatory study was performed on male albino rats (weight range: 180–250 g). The animals were housed into three groups ($n = 6$) and maintained on a standard pellet diet. They were fasted overnight prior to the study with water ad libitum.

Optimized IC or pure drug suspension was prepared in a mortar and pestle using sodium carboxy methyl cellulose (Na CMC) equivalent to 0.25% w/w of the drug as the suspending agent. 2 ml dose equivalent to 4mg/kg was administered orally via syringe to each animal in group two (suspension of pure drug) and group three (suspension of IC). An aqueous solution of 0.25% Na CMC was administered to the control group (group one). Each dose was followed by 1 ml of distilled water to wash off any drug remaining in the upper alimentary tract.

Edema was induced by injecting 0.1 mL of carrageenan (1% w/v prepared in 0.9% w/v saline) into sub plantar tissue of right hind-paw of each rat. The paw of each animal was marked at the same level over the lateral malleolus. The volume of the treated paw was measured at hourly intervals from 0 to 5 hours plethysmometrically by submersion in a mercury bulb. The percent swelling of the carrageenan injected paw was calculated using the formula given below:

$$\% \text{ Swelling} = \frac{(V \text{ treated} - V \text{ untreated})}{V \text{ untreated}}$$

The percent inhibition of swelling was determined in each case using the formula:

$$\% \text{ Inhibition of Swelling} = \frac{\{\% \text{ Swelling (control)} - \% \text{ Swelling (test)}\} \times 100}{\% \text{ Swelling (control)}}$$

The % inhibition of swelling values were plotted against time in hours to get a comparative anti-inflammatory profile of the samples under investigation.

Analgesic activity

The abdominal writhing test in mice was carried out to compare the analgesic activity of MLX and optimized IC. The study was performed on albino mice (weight range: 25 – 30 g). The animals were housed into three groups ($n = 6$) and maintained on a standard pellet diet. They were fasted overnight prior to the study with water ad libitum. IC or pure drug suspension was prepared in a mortar and pestle using sodium carboxy methyl cellulose (Na CMC) equivalent to 0.25% w/w of the drug as the suspending agent. 0.5 ml dose (equivalent to 4mg MLX/kg) was administered orally via syringe to each animal in group two (suspension of pure drug) and group three (suspension of IC). An aqueous solution of 0.25% Na CMC was administered to the control group (group one). Each dose was followed by 0.5 ml of distilled water to wash off any drug remaining in the upper alimentary tract.

Acetic acid (0.7% v/v; 10 ml/kg) was injected intraperitoneally at various time intervals viz. 10, 20, 30 or 40 minutes after oral administration. The mice were immediately placed individually in upturned transparent acrylic chambers and the number of writhes those made from 5 minutes following the acetic acid injection was counted until 20 minutes. (A writhe is defined as an assumption of the posture of flattened abdomen, stretching of hind limbs and depression of back. One writhe is considered to be the adoption of this posture and is terminated upon attainment of normal posture). The anti-nociceptive efficacy of the samples was evaluated as percent protection using the formula given below:

$$\% \text{ Protection} = 100 - \frac{\{\text{Writhes of experimental group}\} \times 100}{\{\text{Writhes of control group}\}}$$

RESULTS AND DISCUSSION

Phase Solubility Studies

The plot of drug solubility against increasing β CD concentrations investigated at $25 \pm 1^\circ\text{C}$ is represented in figure 1. The solubility curve was classified as A_1 type according to Higuchi and Connors. Solubility of pure MLX in water at 25°C was found to be only $9.4 \mu\text{g}/\text{mL}$. The extent of interaction between the drug and the carrier in

aqueous media characterized by the apparent stability constant $K_{1:1}$, calculated according to the equation given by Higuchi and Connors, was found to be 22.056 M^{-1} whereas the Gibbs free energy (ΔF°) was -7.665 kJ/mole . The results confirmed the solubility enhancement capability of β CD, as the solubility of MLX increased linearly with increasing carrier concentration. The negative nature of the Gibbs free energy is indicative of the spontaneous process of solid solution formation process.




Fig. 1: Phase solubility diagram of MLX with β CD (n=6)

Drug content Analysis

Content analysis of all the samples confirmed that MLX could be found to a level of 99.18 to 101.32% (RSD < 2%) of the theoretically added amount in various drug-carrier combinations.

In vitro dissolution studies

The dissolution profiles of MLX, PMs and ICs are depicted in figure 2. Tween 80 (0.02%w/v) was found to be optimum as a wetting and suspending agent. The initial dissolution rate of pure MLX was extremely slow and erratic with only 6.48 (± 2.36) % of the drug dissolved in 10 minutes and 17.91 (± 1.18) % dissolution at the end of one hour. This could be due to its highly hydrophobic nature and poor wettability. Rapid dissolution is a characteristic behavior

observed for various β CD inclusion complexes. It was noted that the ICs showed a faster release as compared with the pure drug and PM. The dissolution parameters of all the samples under study are listed in table 1. The release pattern of PM was better than pure MLX, due to the presence of β CD, however significantly less than that of ICs. The rate of dissolution from ICs was enhanced as the ratio was increased from 2:1 to 1:1M, however further increase in ratio to 1:2M did not show any significant effect on drug release. 1:1 M IC showed 95 (± 2.351) % release at the end of 20 minutes and thus was considered to be optimum for further studies. The improvement in the dissolution rate of the lyophilized system may be attributed to complexation and amorphisation of the drug with β CD, caused by lyophilisation and also due to the hydrophilic property of the carrier which together leads to the increase in wettability and solubility of MLX.




Fig. 2: Dissolution profiles of various MLX- β CD samples (n=6)

Table 1: Dissolution parameters of various MLX- β CD samples

Sample	Time (min.)				First order rate constant	r
	T _{25%}	T _{50%}	T _{75%}	T _{90%}		
MLX	70.61	182.96	374.45	627.78	0.0016	0.9616
MLX- β -CD 1:1M PM	67.93	179.93	371.27	624.19	0.0015	0.9458
MLX- β -CD 2:1M IC	10.18	32.71	85.78	123.71	0.0063	0.9932
MLX- β -CD 1:1M IC	3.76	9.08	15.92	20.44	0.0085	0.9917
MLX- β -CD 1:2M IC	2.35	8.59	15.28	19.87	0.0091	0.9893

DSC studies

DSC enables quantitative detection of all processes in which energy is required or produced (i.e. endothermic and exothermic phase transformations). To characterize possible interactions between the drug and β CD in the solid state, DSC thermogram of MLX, β CD, MLX- β CD PM and MLX- β CD IC (1:1M) were recorded (figure 3). The DSC graph of pure MLX showed a sharp endothermic peak at 268.5°C, which is indicative of its melting temperature. The thermogram of

β CD depicts a melting endotherm at 67.9°C, whereas that of PM, shows an addendum of peaks of both the pure compounds. The thermogram of IC exhibited complete disappearance of the endothermic peak characteristic of the drug; which can be attributed to its amorphous character in the complex state; strongly indicating that the drug is well dispersed in β CD matrix and its re-crystallization is restrained. The results of thermal analysis are thus suggestive of maximal complex formation of the drug and the carrier.




Fig. 3: DSC thermogram of [A] β CD; [B] MLX; [C] MLX- β CD 1:1M PM and [D] MLX- β CD 1:1M IC

XRD studies

The XRD pattern of MLX and β CD (figure 4) showed peaks that were intense and sharp; indicating their crystalline nature while that of the PM was found to be a combination of the drug and β CD, with little decrease in the peak intensity. However, the XRD pattern of the MLX- β CD IC was found to be diffused. Crystallinity

was determined by comparing prominent representative peak heights in the diffraction patterns of the IC with those of MLX and PM. The characteristic peaks at 15.5°, 17.5°, 22°, 23°, 24.5° and 28° (2 θ) observed in figure 4A for MLX are significantly diminished in the complex (figure 4D) thus confirming the formation of a new amorphous solid phase in the inclusion complex.




Fig. 4: X ray diffractogram of [A] β CD; [B] MLX; [C] MLX- β CD 1:1M PM and [D] MLX- β CD 1:1M IC

FTIR studies

FTIR spectral studies were employed to confirm complexation of MLX with β CD. The spectra of the IC was compared with that of MLX, β CD and PM (figure 5). The intense peaks appearing in the spectra of MLX and β CD are due to the asymmetric stretching vibrations of their functional groups. The IR spectrum of β CD (figure 5A) shows prominent peaks at 3389.64 cm^{-1} (O-H), 2924.86 cm^{-1} (C-H), 1649.90 cm^{-1} (H-O-H bending), 1157.71 cm^{-1} (C-O) and 1028.51 cm^{-1} (C-O-C). The IR spectrum of pure MLX (figure 5B) showed characteristic principle peaks at 1529.10 cm^{-1} (aromatic -C-C-), 3085.49 cm^{-1} (aromatic -C-H-), 2930.11 cm^{-1} (C-H aliphatic), as well as at 1346.43 cm^{-1} (-S=O), 3292.79 cm^{-1} (-S-N-) and 1620.35 cm^{-1} (-N-H-). The spectrum of the PM (figure 5C) showed a summation effect i.e. simple superposition of the peaks due to the functional groups of the two compounds, indicating the presence of MLX in crystalline state. In the

spectrum of MLX- β CD IC (figure 5D), the presence and absence of characteristic peaks associated with specific structural characteristics of the drug molecule were noted, however; there were no new peaks, indicating any new chemical bond formation between the two in solid state. The spectrum of the complex showed appearance of an intense broad peak at 3431.2 cm^{-1} . This peak broadening indicates possible hydrogen bonding between MLX and β CD. Shifts are seen in the peak of the aromatic -C-H- (2927.1 cm^{-1}) and aromatic -C-C- (1568.4 cm^{-1}) stretching of the benzene ring, suggesting that these groups are taking part in hydrogen bonding leading to entrapment of the aromatic ring of the guest molecule in the hydrophobic cavity of the host, whereas the sulfide (1353.6 cm^{-1}) and amide group (1626.4 cm^{-1}) peaks do not exhibit any significant contribution in the hydrogen bonding process. These chemical shifts could be attributed to the physical interaction of the drug with β CD which in turn enhance wettability, aqueous solubility and dissolution of the drug.




Fig. 5: FTIR spectra of [A] β CD; [B] MLX; [C] MLX- β CD 1:1M PM and [D] MLX- β CD 1:1M IC

Pharmacodynamic studies

Anti-inflammatory activity

IC, at dose equivalent to 4 mg/kg of MLX, showed greater inhibition in carrageenan-induced hind paw edema as compared to MLX alone (figure 6). The inhibitions of edema were analyzed statistically by one-way ANOVA (SPSS Inc. Statistics 17.0). The % inhibition was

significantly high in IC compared to the inhibition of plain MLX ($P < 0.05$) as shown in table 2. Also IC showed maximum % inhibition of edema at the end of 2 hours (64.48% \pm 3.92) whereas plain MLX showed maximum % inhibition of edema at the end of 4 hours (39.75% \pm 4.73), which was significantly less than that shown by IC. These results strongly suggest a faster onset of action and a better therapeutic response from IC compared to MLX alone.




Fig. 6: Effect of MLX and MLX- β CD 1:1M IC on carrageenan-induced hind paw edema in rats (n=6)


Table 2: Effects of plain MLX and its 1:1 M inclusion complex with β -CD on carrageenan-induced hind paw edema in rats.

Time interval (hr.)	% edema inhibition	
	MLX	MLX- β -CD 1:1M IC
1	8.63 \pm 2.84	33.51 \pm 4.85
2	11.86 \pm 3.74	63.36 \pm 5.23
3	28.39 \pm 5.38	55.95 \pm 3.61
4	39.75 \pm 4.73	42.86 \pm 2.84
5	38.52 \pm 4.39	36.51 \pm 4.97

Analgesic activity

The IC, at dose equivalent to 4 mg/kg of MLX, showed greater inhibition in acetic acid induced writhing as compared to MLX alone (figure 7). The reduction in writhing's were analyzed statistically by one-way ANOVA (SPSS Inc. Statistics 17.0). The analgesic activity, calculated in terms of % protection was significantly high in IC

compared to that of plain MLX ($P < 0.05$). In case of plain MLX there was a gradual increase in anti-nociceptive efficacy with increase in time, reaching a maximum (38.14%) at 40 minutes. Whereas, IC showed maximum efficacy (75.18%) in 20 minutes. The data (Table 3) revealed the fact that extent of protection offered by IC was much higher compared to that of plain MLX, suggesting faster absorption of the drug from the complex compared to the pure drug.

Fig. 7: Effects of plain MLX and MLX- β -CD 1:1M IC on acetic acid-induced writhes in mice (n=6).Table 3: Effects of plain MLX and its 1:1 M inclusion complex with β -CD on acetic acid induced writhing in mice.

Sample	Time (min.)	Abdominal constriction	% inhibition of writhes
Control	-	42.91 \pm 4.33	-
MLX	10	37.8 \pm 3.94	11.78
	20	30.6 \pm 3.08	20.91
	30	33.9 \pm 4.53	27.66
	40	20.7 \pm 3.76	38.14
MLX- β -CD 1:1M IC	10	30.8 \pm 4.65	42.11
	20	19.5 \pm 4.18	74.52
	30	26.1 \pm 2.86	52.65
	40	9.5 \pm 4.42	19.62

CONCLUSION

The cyclodextrin complexation technology serves as an important tool in the current armamentarium of agents for relief of pain and inflammation. It is evident from the in vitro physico chemical characterization and in vivo pharmacodynamic studies performed, that the complexation process not only enhances the aqueous solubility and dissolution of MLX, but also offers the triple advantage of improved gastrointestinal tolerability, significantly faster onset of action and better efficacy as compared to the pure drug. Thus, the inclusion phenomenon should be further explored for production of more efficacious and safe cyclodextrin based commercial formulations and better patient care in future.

REFERENCES

- Hawkey CJ, Cullen DJ, Greenwood D.C: Prescribing of non-steroidal anti-inflammatory drugs in general practice: determinants and consequences. *Alimentary Pharmacology and Therapeutics* 1997; 11: 293-298.
- Griffin MR, Yared A, Ray WA: Non-steroidal anti-inflammatory drugs and acute renal failure in elderly persons. *American Journal of Epidemiology* 2000; 151(5): 488-496.
- Hernandez-Diaz S, Rodriguez LG: Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation. *Archives of Internal Medicine* 2000; 160: 2093-2099.
- Hawke CJ: COX-2 inhibitors. *Lancet* 1999; 353:307-314.
- Gates BJ, Nguyen TT, Setter SM, Davies NM: Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. *Expert Opin. Pharmacother.* 2005; 6 (12): 2117-2140.
- Noble S, Balfour JA: Meloxicam. *Drugs* 1996; 51(3): 424 - 431.
- Luger P, Daneck K, Engel W, Trummlitz G, Wagner K: Structure and physicochemical properties of Meloxicam, a new NSAID. *Eur. J. Pharm. Sci.* 1996; 4 (3) :175-187.

8. Turck D, Roth W, Busch U: A Review of the Clinical Pharmacokinetics of Meloxicam. *Brit. J. Rheumatol.* 1996; 35 : 13-19.
9. Loftsson T, Duchene D: Cyclodextrin and their pharmaceutical applications. *Int. J. Pharm.* 1996; 329: 1-11.
10. Miro A, Quaglia F, Giannini L, Cappello B, La Rotonda M: Drug/cyclodextrin solid systems in designing hydrophilic matrices. A strategy to modulate drug delivery rate. *Curr. Drug Deliv.* 2006; 3: 373-378.
11. Christian L, Jennifer D: Improving drug solubility for oral delivery using solid dispersions. *Eur. J. Pharm. Biopharm.* 2000; 50: 47-60.
12. Pinnamaneni S, Das NG, Das SK: Formulation approaches for orally administered poorly soluble drugs. *Pharmazie* 2002; 57: 291 - 300.
13. Hamsaraj K, Vikram S, Rayasa R: Industrially Feasible Alternative Approaches in the Manufacture of Solid Dispersions: A Technical Report. *AAPS Pharm Sci. Tech.* 2006; 7(4): 87-92.
14. Sethia S, Squillante E: Solid dispersions: revival with greater possibilities and applications in oral drug delivery. *Crit. Rev. Ther. Drug Carrier Syst.* 2003; 20: 215-247.
15. Vasconcelos T, Sarmento B, Costa P: Solid dispersions as strategy to improve oral bioavailability of poorly water soluble drugs. *Drug Discov. Today*, 2007; 12 (23): 1068-1075.
16. Mosher G, Thompson D: Complexation and cyclodextrins. In: *Encyclopedia of pharmaceutical technology*, 2nd ed., Marcel Dekker Inc., New York, 2002, 531 - 558.
17. Loftsson T, Brewster M: Pharmaceutical applications of cyclodextrins. Drug solubilization and stabilization. *J. Pharm. Sci.* 1996; 85: 1017-1025.
18. Brewster ME, Loftsson T: Cyclodextrins as pharmaceutical solubilizers. *Adv. Drug Deliv. Rev.* 2007; 59: 645-666.
19. Ahuja A, Challa R, Khar RK, Ali J: Cyclodextrins In drug delivery: an updated review. *APS Pharm. Sci. Tech.* 2005; 6: 2-8.
20. El-Maradny HA, Mortada SA, Kamel OA, Hikal AH: Characterization of ternary complexes of meloxicam-HP- β -CD and PVP or L-arginine prepared by the spray-drying technique. *Acta. Pharm.* 2008; 58: 455-466.
21. Buchi N, Nalluri KP, Chowdary KV, Murthy R, Becket G, Crooks P: Tablet Formulation Studies on Nimesulide and Meloxicam-Cyclodextrin Binary Systems. *AAPS Pharm. Sci. Tech.* 2007, 8 (2): 36 -42.
22. Kumar SG, Mishra DN: Preparation, characterization and in vitro dissolution studies of solid dispersion of meloxicam with PEG. *J. Pharm. Soc. Jpn.* 2006; 126 : 657-664.
23. Baboota S, Agarwal SP: Inclusion complexation of meloxicam with β -cyclodextrin. *Ind. J. Pharm. Sci.* 2002; 64(4): 408-411.
24. Obaidat AA, Khanfar RA, Khawam MN: The effect of β -cyclodextrin on the solubility and dissolution rate of Meloxicam and investigation of the driving force for complexation using molecular modeling. *J. Incl. Phenom. Macro. Chem.* 2009; 63(3): 273-279.
25. Rangasamy M, Balasubramaniam A, Gummadevelly S: Design and evaluation of β -cyclodextrin complexes of meloxicam tablet. *Research J. Pharma. Tech.* 2008; 1(4): 484-486.
26. Nath BS, Shiva-Kumar HN: A 2(3) factorial studies on factors influencing meloxicam β -cyclodextrin complexation for better solubility. *Ind. J. Pharm. Sci.* 2000; 62 (2): 129-132.
27. Ghorab MM, Abdel-Salam HM, El-Sayad MA, Mekhel MM: Tablet Formulation Containing Meloxicam and β -Cyclodextrin: Mechanical Characterization and Bioavailability Evaluation. *AAPS Pharm. Sci. Tech.* 2004; 5 (4): 59 - 63.
28. Inamdar N, Bhise K, Memon S: Solubility enhancement and development of dispersible tablet of meloxicam. *Asian Journal of Pharmaceutics*, 2008; 4: 128-132.
29. Yu L: Amorphous pharmaceutical solids: Preparation, characterization and stabilization. *Adv. Drug Deliv. Rev.* 2001; 48 (1): 27-42.
30. Kaushal AM, Gupta P, Bansal AK: Amorphous drug delivery systems: molecular aspects, design and performance. *Crit. Rev. Ther. Drug Carrier Syst.* 2004; 21 (3)133-139.
31. Buchi N, Chowadry KPR, Murthy KVR, Satyanarayana V, Hayman AR, Becket G: Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. *J. Pharm. Biomed. Anal.* 2004; 35: 75-86.
32. Chowdary KPR, Raviprakash P: Dissolution kinetics of meloxicam- β -cyclodextrin complex system. *Int. J. Chem. Sci.* 2006; 4: 845-848.
33. Bandarkar FS, Vavia PR: An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β -cyclodextrin. *Drug Development and Industrial Pharmacy* 2011; 37 (11): 1318-1328.
34. Maski N, Kumaran A, Girhepunje K, Ghode P, Randive S, Pal R: Studies on the preparation, characterization and solubility of β -cyclodextrin-Diacerein inclusion complexes. *International Journal of Pharmaceutics and Pharmaceutical Sciences*; 2009, 1 (2):121 - 135.
35. Higuchi T, Connors K: Phase-solubility techniques. In: *Reilley, C.N.: Advanced Analytical Chemistry and Instruments*, Vol. 4, New York: John Wiley and Sons, 1965, 117-212.
36. Connors KA: *Binding Constants: The Measurement of Molecular Complex Stability*. Wiley, London, 1987, 261-281.
37. Vavia PR, Adhage NA: Cyclodextrin inclusion complexation by milling. *Pharm. Pharmacol. Commun.* 2000, 6, 13-18.
38. Ranpise NS, Kulkarni NS, Mair PD, Ranade AN: Improvement of water solubility and in vitro dissolution rate of aceclofenac by complexation with β -cyclodextrin and hydroxypropyl- β -cyclodextrin. *Pharmaceutical Development and Technology* 2010; 15(1), 64-70.
39. Aejaaz A, Jafar M, Dehgan M, Adil S: Meloxicam-PVP-SLS Ternary dispersion systems: in-vitro and in-vivo evaluation. *International Journal of Pharmaceutics and Pharmaceutical Sciences*; 2010, 2(1):182 - 190.